Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

PURPOSE: The AVAglio trial established the beneficial effect of add-on bevacizumab (BEV) for the treatment of newly diagnosed glioblastomas (nd-GBMs) that led to the approval of BEV for the treatment of these patients in Japan. However, the rationality of using BEV as a first-line treatment for nd-G...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Hata, Nobuhiro, Yoshimoto, Koji, Hatae, Ryusuke, Kuga, Daisuke, Akagi, Yojiro, Sangatsuda, Yuhei, Suzuki, Satoshi O, Shono, Tadahisa, Mizoguchi, Masahiro, Iihara, Koji
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2017
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5261854/
https://ncbi.nlm.nih.gov/pubmed/28176936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S125587
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky